At 14 weeks of age, mice were randomized into treatment groups ( n = 8 per group) receiving subcutaneous injections of PG-102 (15, 30, 60, or 120 nmol/kg), semaglutide (30 nmol/kg), tirzepatide (15 nmol/kg), or vehicle every 3 days for 12 weeks
It is also non-invasive, which reduces the likelihood of complications typically associated with more aggressive treatments
Think of it this way: if your heart's electrical system is like a house's wiring, a B12 deficiency might cause a "brownout" (like anemia-induced tachycardia), but there could be other wiring issues your device can spot, too
My biggest problem with ADHD is I am the biggest procrastinator, a Reddit user wrote
All content was reviewed and selected by the Irish Endocrine Committee, which held full responsibility for the abstract selection